Form of parathyroid hormone released continuously over 24 hours. Replaces the missing hormone in chronic hypoparathyroidism in adults.
Regulatory status
Approved (FDA / EMA)
Family
Sustained-release PTH(1-34) prodrug
Scientific evidence
High
Number of findings
2
Where it acts
Hormones and metabolism · Bones and muscles · Heart and blood
Also known as
palopegteriparatide, TransCon PTH, Yorvipath
Regulatory status
FDA (US): Approved (2024, Yorvipath) for hypoparathyroidism in adults.
EMA (EU): Approved (2023, Yorvipath) for chronic hypoparathyroidism in adults.
Dose
Start with 18 µg subcutaneously once a day, adjusting in 3 µg steps according to blood calcium, within a range of 6–60 µg/day (FDA Yorvipath label).
Safety
Injection-site reactions, headache, dizziness, orthostatic hypotension; risk of high or low calcium during adjustments. Calcium must be monitored frequently when starting or changing the dose. Only under endocrinology supervision.
Interactions
Digoxin is more toxic if calcium changes; thiazide diuretics and other drugs that affect calcium may require dose adjustment.
Effect by goal · level of evidence
Normal calcium without conventional treatment
improvesHighRCT (AA)in people
79% vs 5%
Phase 3 PaTHway with 84 adults over 26 weeks: 79% met the composite endpoint (normal calcium without therapeutic doses of calcium or active vitamin D) versus 5% with placebo. 93% stopped conventional treatment.
In the 52-week open-label extension (78 patients), 81% maintained the endpoint and 95% remained free of conventional treatment; none needed active vitamin D.
It is teriparatide (PTH 1-34) attached to a carrier from which it is released gradually. This keeps PTH levels stable throughout the day, as the healthy gland does. It normalizes blood calcium and reduces the need for high doses of calcium and active vitamin D.
What the evidence says
In people
Normal calcium without conventional treatment. Phase 3 PaTHway trial with 84 adults over 26 weeks: 79% met the combined endpoint (normal calcium without therapeutic doses of calcium or active vitamin D) versus 5% with placebo. 93% stopped conventional treatment. PubMed 36271471
One-year maintenance. In the 52-week open-label extension (78 patients), 81% maintained the endpoint and 95% remained off conventional treatment; none needed active vitamin D. PubMed 39376010